Seeking Alpha

Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of...

Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of tivantinib in patients with refractory or relapsed colorectal cancer, Burrill Institutional Research thinks its use in treating hepatocellular carcinoma (HCC) could still drive shares higher. In patients with HCC, Tivantinib demonstrated statistically significant results versus a placebo in reducing tumor progression, and the firm thinks the treatment could reach global peak sales of $278M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|